DSpace Repository

Targeted killing of prostate cancer cells using antibody–drug conjugated carbon nanohorns

Show simple item record

dc.contributor.author Herrero, María Antonia
dc.contributor.author Lucío, María Isabel
dc.contributor.author Opri, Roberta
dc.contributor.author Pinto, Marcela
dc.contributor.author Fierro, José L.G.
dc.contributor.author Meneghetti, Moreno
dc.contributor.author Fracasso, Giulio
dc.contributor.author Prato, Maurizio
dc.contributor.author Vazquez, Ester
dc.contributor.author Scarsi, Alessia
dc.date.accessioned 2018-05-02T12:28:29Z
dc.date.available 2018-05-02T12:28:29Z
dc.date.issued 2017-10-17
dc.identifier.citation Journal of material Chemistry, B es_ES
dc.identifier.issn 2050-750X
dc.identifier.uri http://hdl.handle.net/10578/17414
dc.description.abstract The ability of carbon nanohorns (CNHs) to cross biological barriers makes them potential carriers for delivery purposes. In this work, we report the design of a new selective antibody-drug nanosystem based on CNHs for the treatment of prostate cancer (PCa). In particular, cisplatin in a prodrug form and the monoclonal antibody (Ab) D2B, selective for PSMA+ cancer cells, have been attached to CNHs due to the current application of this antigen in PCa therapy. The hybrids Ab-CNHs, cisplatin-CNHs and functionalised- CNHs have been also synthesized to be used as control systems. The efficacy and specificity of the D2B-cisplatin-CNHs conjugate to selectively target and kill PSMA+ prostate cancer cells have been demonstrated in comparison with the other derivatives. The developed strategy to functionalise CNHs is fascinating because it can allow a fine tuning of both drug and Ab molecules attached to the nanostructure in order to modulate the activity of the nanosystem. Finally, the herein described methodology can be used for the incorporation of almost any drugs or Abs in the platforms in order to create new targeted drugs for the treatment of different diseases. es_ES
dc.format application/pdf es_ES
dc.language.iso en es_ES
dc.publisher Royal Society of Chemistry es_ES
dc.rights info:eu-repo/semantics/openAccess es_ES
dc.subject Nanomaterials es_ES
dc.subject Nanohorns es_ES
dc.subject Drug delivery es_ES
dc.subject Antobody es_ES
dc.subject Cancer es_ES
dc.title Targeted killing of prostate cancer cells using antibody–drug conjugated carbon nanohorns es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.relation.projectID EU Graphene-based disruptive technologies, Flagship project (no. 696656). es_ES
dc.relation.projectID Spanish Ministry of Economy and Competitiveness MINECO (projects CTQ2014-53600-R and CTQ2016-76721-R es_ES
dc.relation.projectID Fondazione Cariverona, Verona Nanomedicine Initiative and Italian Minister of Health RF-2010- 2305526 es_ES
dc.identifier.DOI 10.1039/c7tb02464a

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account